April 4, 2017, San Diego and Beijing — Novogene Corporation, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, today announced that its next-generation sequencing (NGS) medical lab in Tianjin, China has received accreditation from the College of American Pathologists (CAP). With CAP accreditation, Novogene now will be able to provide its high-quality, well-established clinical sequencing services to customers throughout the world.
The process of CAP accreditation involves a rigorous series of inspections and certifications on lab quality management systems, experimental processes, data analysis and clinical interpretation. CAP accreditation, received on March 30th, 2017, attests to Novogene Tianjin medical lab’s global comparability and competitiveness for NGS sample quality control, personnel qualification, facilities, and quality assurance.
Novogene established its clinical service division in January 2014, and has continuously developed its clinical services in China, including tumor gene detection and genetic testing services. Novogene also established a Precision Medicine Center of Excellence with Thermo Fisher Scientific in December 2016 and is one of the first China National Genetic Testing Technology Demonstration Centers.
“Our strategy is to incorporate scientific research, clinical diagnostics, and preventive medicine synergistically to drive life science research and improve human healthcare,” stated Dr. Ruiqiang Li, CEO of Novogene. “CAP accreditation represents an important milestone for our Tianjin medical center, which can now provide superior clinical services to our more than 450 hospital customers and pharmaceutical partners globally for projects of any scale, in ways that we could not before.”
About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,300 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journals such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit http://en.novogene.com/.
Joyce Peng, Ph.D.
Global Marketing Director